Ginkgo Bioworks Holdings, Inc. (DNA) is a Boston-based synthetic biology company that has repositioned itself around autonomous laboratory infrastructure — selling robotic lab systems to pharmaceutical and government customers and renting out capacity at its own Boston facility, Nebula. On Monday, the stock fell 9.68% to $8.68, compared with Friday's close of $9.61. The decline was confirmed in both direction and magnitude, and it extends a slide that has now erased roughly 30% of the share price since the November 9 close. No verified news catalyst was found for the session; the move instead reflects the continued deflation of a post-earnings speculative run in a highly volatile, heavily shorted micro-cap.
No verified news or fundamental catalyst found to explain Monday's decline. There was no press release, no 8-K, no financing announcement, and no regulatory development tied to the move. The most defensible assessment is technical: the stock is giving back the last remnants of an earnings-driven spike that briefly doubled the share price between late September and early October, when it ran from about $7.90 to an intraday high of $18.22 on October 6.
Two data points support that read. First, the stock had already fallen in six of the prior seven sessions, sliding from $12.37 on November 9 to $9.61 on November 13, so Monday's drop continued an established downtrend rather than starting a new one. Second, the decline carried the shares to $8.55 intraday, essentially touching the 200-day moving average near $8.64 — a level that has acted as a floor through the autumn rally. A move of this size is also routine for this name: the stock has posted daily swings of 9.7% or more on 18 of the last 69 sessions.
Third-quarter results, released November 5, were genuinely better than expected: revenue of $27.7 million beat consensus of about $21.5 million, the net loss from continuing operations narrowed to $41 million from $73 million, and adjusted EBITDA loss improved 58% year over year. The stock jumped 13% the next session. But the beat leaned on a contract modification that pulled revenue forward, total revenue was still down 6% year over year, and management declined to issue 2027 guidance until February.
That gap gave sell-side analysts little to defend. TD Cowen moved to Hold from Buy with an $11 target, BTIG reiterated a Sell rating and a $5 target, and the broader consensus now sits at underperform with an average target of $8.00 — implying further downside from current levels. Short interest stands at roughly 9.5 million shares, or about 15% of shares outstanding, leaving the name prone to sharp two-way moves as positioning shifts.
Volume was elevated. Roughly 262,000 shares traded in the first fifteen minutes, a pace well above the 20-day average of about 2.5 million shares spread across a full session. The stock opened near $9.31 and sold off in the first half hour rather than gapping lower overnight, which points to active institutional distribution during regular hours rather than an overnight headline.
The move was idiosyncratic. There was no matching catalyst among large-cap biotech peers or lab-automation names, and no confirmed sector-wide event. Ginkgo's beta of 1.74 to 2.6 — depending on the measurement window — means it routinely amplifies broader risk sentiment, and the shares have historically sold off alongside genomics-focused exchange-traded funds during bouts of biotech risk aversion.
The scale runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. This event scores 19 out of 100. The verified news component is weak: there was no announcement on Monday, and the most relevant fundamental information — the earnings beat and the subsequent analyst downgrades — is more than a week old and already reflected in the price.
The price component is also modest in context. Monday's 9.68% decline was roughly 1.6 times the stock's average absolute daily move of 6.2% over the past 60 sessions, and moves of similar or larger size occurred 18 times in that window. Two weak components combine into a low score.
The next hard catalyst is the fourth-quarter report and, more importantly, 2027 guidance, expected around late February. Management has said it will reset expectations then, including any revenue framework for autonomous-lab hardware and recurring Cloud Lab services. Investors will also watch the cash burn trajectory against full-year guidance of $125 million to $150 million, backed by $285 million in cash and marketable securities with no bank debt.
Commercially, the focus is conversion: the first autonomous-lab sale to Novo Nordisk (NVO), an ARPA-H subcontract worth up to $17.5 million, and cloud-lab customer additions need to translate into revenue. Risks include continued top-line contraction, competition from low-cost contract research organizations, and the possibility that valuation continues to compress toward the analyst consensus target.
Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions earn a place in the curated Trending AI Robots section. Bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the leaders in this list change as market conditions shift. For investors navigating volatile names like this one, it is a practical starting point for comparing live, rules-based strategies side by side.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Be on the lookout for a price bounce soon.
Following a +24.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where DNA advanced for three days, in 209 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DNA as a result. In 73 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for DNA turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 41 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
DNA moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for DNA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.809) is normal, around the industry mean (3.592). P/E Ratio (-2.258) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (3.397) is also within normal values, averaging (442.120).
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. DNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology